Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.52 Billion JPY | -346.87% |
| 2022 | 3.67 Billion JPY | -8.8% |
| 2021 | 4.02 Billion JPY | 82.91% |
| 2020 | 2.2 Billion JPY | 114.22% |
| 2019 | 1.02 Billion JPY | 113.88% |
| 2018 | -7.4 Billion JPY | -223.06% |
| 2017 | -2.29 Billion JPY | -118.49% |
| 2016 | 12.38 Billion JPY | 1052.47% |
| 2015 | 1.07 Billion JPY | -3.05% |
| 2014 | 1.1 Billion JPY | 46.6% |
| 2013 | 756.39 Million JPY | 179.33% |
| 2012 | -953.43 Million JPY | 51.42% |
| 2011 | -1.96 Billion JPY | -4.61% |
| 2010 | -1.87 Billion JPY | -1.16% |
| 2009 | -1.85 Billion JPY | 49.43% |
| 2008 | -3.66 Billion JPY | 41.5% |
| 2007 | -6.26 Billion JPY | 5.73% |
| 2006 | -6.65 Billion JPY | -50.93% |
| 2005 | -4.4 Billion JPY | -151.33% |
| 2004 | -1.75 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -888 Million JPY | 73.83% |
| 2024 Q3 | 541 Million JPY | 160.92% |
| 2024 Q1 | -3.39 Billion JPY | -128.95% |
| 2023 Q2 | -2.2 Billion JPY | -30.34% |
| 2023 FY | -9.06 Billion JPY | -346.87% |
| 2023 Q3 | -3.45 Billion JPY | -56.94% |
| 2023 Q1 | -1.69 Billion JPY | -138.28% |
| 2023 Q4 | -1.48 Billion JPY | 57.16% |
| 2022 FY | 3.67 Billion JPY | -8.8% |
| 2022 Q4 | 4.41 Billion JPY | 38.99% |
| 2022 Q3 | 3.17 Billion JPY | 297.02% |
| 2022 Q2 | -1.61 Billion JPY | 30.11% |
| 2022 Q1 | -2.3 Billion JPY | -130.15% |
| 2021 FY | 4.02 Billion JPY | 82.91% |
| 2021 Q4 | 7.65 Billion JPY | 422.18% |
| 2021 Q3 | -2.37 Billion JPY | -288.87% |
| 2021 Q1 | -1.23 Billion JPY | -157.72% |
| 2021 Q2 | -611 Million JPY | 50.65% |
| 2020 FY | 2.2 Billion JPY | 114.22% |
| 2020 Q1 | -445 Million JPY | 37.32% |
| 2020 Q2 | -691 Million JPY | -55.28% |
| 2020 Q3 | -81 Million JPY | 88.28% |
| 2020 Q4 | 2.14 Billion JPY | 2748.15% |
| 2019 Q2 | -330 Million JPY | -125.33% |
| 2019 Q1 | 1.3 Billion JPY | 165.77% |
| 2019 FY | 1.02 Billion JPY | 113.88% |
| 2019 Q3 | 363 Million JPY | 210.0% |
| 2019 Q4 | -710 Million JPY | -295.59% |
| 2018 Q3 | -1.97 Billion JPY | -10.49% |
| 2018 FY | -7.4 Billion JPY | -223.06% |
| 2018 Q2 | -1.78 Billion JPY | 18.84% |
| 2018 Q1 | -2.19 Billion JPY | -42.85% |
| 2018 Q4 | -1.98 Billion JPY | -0.56% |
| 2017 Q1 | -244 Million JPY | -159.51% |
| 2017 FY | -2.29 Billion JPY | -118.49% |
| 2017 Q4 | -1.53 Billion JPY | -316.01% |
| 2017 Q3 | 712 Million JPY | -2.6% |
| 2017 Q2 | 731 Million JPY | 399.59% |
| 2016 FY | 12.38 Billion JPY | 1052.47% |
| 2016 Q3 | -732 Million JPY | -105.65% |
| 2016 Q4 | 410 Million JPY | 156.01% |
| 2016 Q2 | 12.95 Billion JPY | 645.7% |
| 2016 Q1 | -2.37 Billion JPY | -162.7% |
| 2015 FY | 1.07 Billion JPY | -3.05% |
| 2015 Q1 | 1.09 Billion JPY | 967.72% |
| 2015 Q2 | -848 Million JPY | -177.67% |
| 2015 Q3 | 511 Million JPY | 160.26% |
| 2015 Q4 | 3.78 Billion JPY | 640.9% |
| 2014 Q4 | 102.26 Million JPY | 1972.21% |
| 2014 Q1 | 1.23 Billion JPY | 368.03% |
| 2014 FY | 1.1 Billion JPY | 46.6% |
| 2014 Q2 | -79.8 Million JPY | -106.46% |
| 2014 Q3 | -5.46 Million JPY | 93.16% |
| 2013 Q4 | -461.18 Million JPY | -170.08% |
| 2013 FY | 756.39 Million JPY | 179.33% |
| 2013 Q2 | -676.6 Million JPY | -8.8% |
| 2013 Q1 | -621.87 Million JPY | -437.22% |
| 2013 Q3 | 658.06 Million JPY | 197.26% |
| 2012 Q1 | -661.1 Million JPY | -7.36% |
| 2012 FY | -953.43 Million JPY | 51.42% |
| 2012 Q2 | -613.96 Million JPY | 7.13% |
| 2012 Q4 | -115.75 Million JPY | -129.07% |
| 2012 Q3 | 398.16 Million JPY | 164.85% |
| 2011 Q4 | -615.76 Million JPY | -286.2% |
| 2011 Q3 | -159.44 Million JPY | 69.71% |
| 2011 Q2 | -526.31 Million JPY | 25.66% |
| 2011 Q1 | -708 Million JPY | -12.94% |
| 2011 FY | -1.96 Billion JPY | -4.61% |
| 2010 Q1 | -694.22 Million JPY | -18.36% |
| 2010 Q2 | 60.5 Million JPY | 108.72% |
| 2010 Q3 | -601.78 Million JPY | -1094.55% |
| 2010 FY | -1.87 Billion JPY | -1.16% |
| 2010 Q4 | -626.9 Million JPY | -4.17% |
| 2009 Q2 | 6.96 Million JPY | 101.24% |
| 2009 Q3 | -580.87 Million JPY | -8435.17% |
| 2009 Q4 | -586.55 Million JPY | -0.98% |
| 2009 FY | -1.85 Billion JPY | 49.43% |
| 2009 Q1 | -560.97 Million JPY | 48.7% |
| 2008 Q4 | -1.09 Billion JPY | -15.3% |
| 2008 FY | -3.66 Billion JPY | 41.5% |
| 2008 Q3 | -948.46 Million JPY | 0.0% |
| 2007 FY | -6.26 Billion JPY | 5.73% |
| 2006 FY | -6.65 Billion JPY | -50.93% |
| 2005 FY | -4.4 Billion JPY | -151.33% |
| 2004 FY | -1.75 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 1696.121% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -1817.209% |
| GNI Group Ltd. | 13.1 Billion JPY | 172.669% |
| Linical Co., Ltd. | 725.72 Million JPY | 1412.62% |
| Trans Genic Inc. | 89.43 Million JPY | 10751.192% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | -568.045% |
| Soiken Holdings Inc. | -610 Million JPY | -1461.621% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -1132.753% |
| AnGes, Inc. | -11.96 Billion JPY | 20.401% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | -749.929% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 9233.357% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -1002.017% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | -752.837% |
| CanBas Co., Ltd. | -1.26 Billion JPY | -654.834% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -1092.9% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -2723.648% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | -690.429% |
| Kidswell Bio Corporation | -1.33 Billion JPY | -613.239% |
| PeptiDream Inc. | 6.77 Billion JPY | 240.646% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | -393.579% |
| Ribomic Inc. | -1.11 Billion JPY | -753.437% |
| SanBio Company Limited | -4.53 Billion JPY | -109.87% |
| Healios K.K. | -3.37 Billion JPY | -181.918% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | -724.705% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -583.597% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -578.974% |
| StemRIM | -2.07 Billion JPY | -358.863% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 879.861% |
| FunPep Company Limited | -994 Million JPY | -858.35% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -971.828% |
| Stella Pharma Corporation | -760.3 Million JPY | -1152.926% |
| TMS Co., Ltd. | -943.25 Million JPY | -909.909% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -1128.541% |
| Cuorips Inc. | -588.48 Million JPY | -1518.727% |
| K Pharma,Inc. | 366.05 Million JPY | 2702.327% |
| Takara Bio Inc. | 3 Billion JPY | 417.216% |
| ReproCELL Incorporated | -409.29 Million JPY | -2227.428% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 86206.843% |
| StemCell Institute Inc. | 413.75 Million JPY | 2402.306% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 6692.068% |
| CellSeed Inc. | -697.77 Million JPY | -1265.195% |